

Gibson Dunn Advised Galecto on Public Offering of Common Stock

Firm News | February 17, 2026

Gibson Dunn advised Galecto, Inc. on its public offering of common stock, which generated aggregate gross proceeds to the company of approximately \$316 million.

Galecto is a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers.

The Gibson Dunn corporate team included partners Ryan Murr, Branden Berns, and Melanie Neary and associates Nicholas Linke, Candice Johnson, Lauren Navarro, and Chad Kang.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Melanie E. Neary](#)

[Nicholas G. Linke](#)

[Candice D. Johnson](#)

[Lauren Navarro](#)

[Chad Kang](#)

Related Capabilities

[Life Sciences](#)